Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. - Wikidata - awgldk - TriplyDB

Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.

Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.

http://www.wikidata.org/entity/Q36266486

about

Highlights from the Seventh International Workshop on HIV Persistence during Therapy, 8-11 December 2015, Miami, Florida, USA Latency reversal and viral clearance to cure HIV-1.Lessons learned from human HIV vaccine trials.Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection CD19xCD3 DART protein mediates human B-cell depletion in vivo in humanized BLT mice Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency.Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors.HIV-1 Latency and Eradication: Past, Present and Future Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies International AIDS Society global scientific strategy: towards an HIV cure 2016.Landscape review of current HIV 'kick and kill' cure research - some kicking, not enough killing.Engineering broadly neutralizing antibodies for HIV prevention and therapy.IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis.Use of broadly neutralizing antibodies for HIV-1 prevention.What can we do to reduce the viral reservoir in HIV-1-infected individuals?Cancer therapies in HIV cure research.Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection Bispecific antibodies for viral immunotherapy.HIV antibodies for treatment of HIV infection.Novel AIDS therapies based on gene editing.Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents.In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells.Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies.Beyond Viral Neutralization.A Highly Conserved Residue of the HIV-1 gp120 Inner Domain Is Important for Antibody-Dependent Cellular Cytotoxicity Responses Mediated by Anti-cluster A Antibodies HIV: Cure by killing.Highlights from the Third Biennial Strategies for an HIV Cure Meeting: 14-16 November 2016, Bethesda, MD, USA.The making of bispecific antibodies Patterns of conserved gp120 epitope presentation on attached HIV-1 virions.Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.Cell and Gene Therapy for HIV Cure.T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.The Antiviral Immune Response and Its Impact on the HIV-1 Reservoir.Immune Interventions to Eliminate the HIV Reservoir.Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific Antibody.Highlights from the 8th International Workshop on HIV Persistence during Therapy, 12-15 December 2017, Miami, FL, USA.Exosomal Tat protein activates latent HIV-1 in primary, resting CD4+ T lymphocytes.

P2860

Q28384231-4AB1463E-6D79-4D8E-BE22-07E7811F9500 Q30248766-185BBFC3-C51F-48CE-B3E8-6198D80AD253 Q33557844-54386E13-DF25-4FC6-84D1-2BEE0BCD0A0C Q33620546-F6CB65D4-E869-4B34-B820-ADA896C3B26D Q36777155-DE95CA10-8278-432E-AFD7-E5361B2C9190 Q37145901-C18DB4E1-89F2-4F35-979E-812AA8F8404F Q37499526-15A22FE1-C20C-48C2-BDC5-67ED85CF7197 Q37505823-4CC61FD6-E4AA-4C17-A7CE-4A50DF480896 Q37621530-77081BE5-C9AE-4ED3-8E16-B0892E520CF9 Q37661770-4F4FD9D0-AFA1-489F-8D3F-B1BC48DAAD59 Q38636019-B8C5B342-9696-4A13-991B-09C820D29888 Q38717198-BC8B3AF1-550E-4DCF-982D-791627A2678E Q38720858-220A5255-5833-4DCD-895A-B37633F63FC5 Q38764543-D9C2D21B-D8FC-493E-8668-43A63C624B8F Q38841879-94B88BFC-C819-43DC-9601-1C876B4D5A34 Q38949445-08421906-F4A5-444F-A0DF-66EB7AC7B50E Q38977425-BFC88EDE-1399-4A3C-8754-616BF1518605 Q38992408-D952F7C2-0104-4080-AA33-0274D035A809 Q39108716-DBEB63BC-1B6C-47D8-828A-65D8A65911F2 Q39140209-EEE10454-F630-4846-88A6-2CAD77C479A7 Q39315697-6D086FC3-B84C-45D9-A516-FBB864D2FCE8 Q39749215-BFB19920-0C9D-4090-9399-C7DEC6660E29 Q40080802-41F253CF-19C4-4A14-BC5D-94B71C10AF73 Q40084640-C2AB965A-80CD-4096-B57D-99C3DBFAFA57 Q40120304-C2586CEB-90C8-46D1-B4DF-0BE30B82C6F2 Q40366328-34358EDB-20E2-4B9D-8398-000CE9DCF88F Q40373085-54829A50-AFA6-425D-B393-6C2469DF8A55 Q40882652-0846143F-5A47-4172-9906-8B922373FD47 Q40884150-E6918D7C-2016-4C70-98AA-13B560B80226 Q42318283-972E6362-785D-4A05-AFDF-2CC88900560C Q42323236-46BEC475-F49B-4124-98EC-08DC5761EC6E Q47109778-CA9EBCC8-CEBD-4ED2-864E-5F06F40A1B14 Q47110966-D12E2123-0E26-4ECE-A82A-DEAE068838FF Q47236016-892CFB60-552A-4883-8658-0C83A3ECF991 Q47570404-E1E57528-B3B4-4B06-9B68-636ED7999506 Q47600020-AD95C44B-3714-41A4-B546-FF45DEC65037 Q47600062-87DC5792-7EDF-4A0B-B10D-6ED2C199FACA Q47610511-8FD6A55B-B3AD-4D06-BDF1-C3068E8FE74A Q52571192-056D0D0F-79BB-4705-8179-D48DB8C6C774 Q52606459-2083DB9B-843E-418B-AD2D-B6726B6B789C

P2860

Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.

http://www.wikidata.org/entity/Q36266486

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Dual-Affinity Re-Targeting pro ...... f latently HIV-infected cells.

@ast

Dual-Affinity Re-Targeting pro ...... f latently HIV-infected cells.

@en

type

label

Dual-Affinity Re-Targeting pro ...... f latently HIV-infected cells.

@ast

Dual-Affinity Re-Targeting pro ...... f latently HIV-infected cells.

@en

prefLabel

Dual-Affinity Re-Targeting pro ...... f latently HIV-infected cells.

@ast

Dual-Affinity Re-Targeting pro ...... f latently HIV-infected cells.

@en

P1433

Q36266486-A37BD67A-0D05-4A7A-A6C9-9E5915C85CC3

P1476

Q36266486-26A223E6-6A01-4558-B1C5-D10B4698BB8B

P2093

Q36266486-0DBC42CA-B33A-4D47-BB62-43F465F22577

Q36266486-0F3BC999-1604-424A-BCC1-FDC39D8B23EA

Q36266486-18529824-C608-4268-873A-48FE29F9F635

Q36266486-1D91CA5B-BBC8-4A97-8C12-FB6DE027E474

Q36266486-40756A4E-735B-45F7-8FB0-DAE0E0BA7536

Q36266486-42C90DEA-C0F0-490C-87BB-00CA969F8C01

Q36266486-4DE6F80A-F823-4709-9D3E-CBCE483362DD

Q36266486-51D27124-7168-4F00-8409-98221F17C9CD

Q36266486-536CD26E-08A9-47FC-AC84-508C3238AE7A

Q36266486-5CB9C1D8-3983-4BC5-A353-D06CBD6F54B1

P2860

Q36266486-01BFF5E8-60A9-46B8-96A6-E1C11938108D

Q36266486-053BE677-8F62-43D4-A082-E397FBFD750B

Q36266486-0C0D5421-3F8E-400D-8459-77BBDED8FEE1

Q36266486-105CEA78-D2EF-4CB6-9694-B9F02C88D80E

Q36266486-1370FCAB-1F57-4871-9D8B-DA04ABE95A65

Q36266486-15B02C37-40E3-44E1-8E90-A09AEC11587E

Q36266486-192ACE51-8F2D-4A81-9F59-5DB82BD2C4B5

Q36266486-1B48DDB4-7795-449E-887C-63D23D2938CF

Q36266486-1F5675A1-5F21-4EE9-8D02-54A70C471310

Q36266486-2539448C-7E60-4420-AA3B-A8B8D94E63BB

P304

Q36266486-42D04694-3BFE-4195-977C-131070C08956

P31

Q36266486-54E793EF-DFD9-439C-BAE3-C568A1BB9A7C

P356

Q36266486-716F9B53-A7EA-4886-8C28-19EA0C3702E9

P407

Q36266486-25C8332D-F948-4DD2-8FFC-308F34DF206C

P433

Q36266486-99753D4F-D381-4815-BC6B-099BE94E148F

P478

Q36266486-F919EFC9-DFF6-4007-8834-69AE791F074F

P50

Q36266486-0F33660F-50FA-4353-8DFF-3D6F919C1ECA

Q36266486-123A6950-F585-4F13-B66A-3419425A2032

Q36266486-329F5165-A44A-4BF7-9FF8-4B1B740695BA

Q36266486-FE0726A3-636D-4BEA-B977-3D5020548039

P577

Q36266486-5960C064-8683-4190-87D0-C4432EEECBFD

P698

Q36266486-45E53EDC-7DE3-4A6C-89E0-3181EF0076F1

P921

Q36266486-CEB1DD39-AE79-4094-8519-80956F3FC060

P932

Q36266486-A8B552CF-0D9C-4BFB-A885-EF71836AA6D3

P356

P1433

Journal of Clinical Investigation

P1476

Dual-Affinity Re-Targeting pro ...... f latently HIV-infected cells.

@en

P2093

Brigitte Allard

http://www.w3.org/2001/XMLSchema#string

Carolina Garrido

http://www.w3.org/2001/XMLSchema#string

Celia LaBranche

http://www.w3.org/2001/XMLSchema#string

Chia-Ying Kao Lam

http://www.w3.org/2001/XMLSchema#string

Christina Ochsenbauer

http://www.w3.org/2001/XMLSchema#string

Cynthia L Gay

http://www.w3.org/2001/XMLSchema#string

David M Margolis

http://www.w3.org/2001/XMLSchema#string

Hua-Xin Liao

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Nordstrom

http://www.w3.org/2001/XMLSchema#string

Jennifer Kirchherr

http://www.w3.org/2001/XMLSchema#string

P2860

Structural Definition of an Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV-1 Infection

Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding

High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies

Targeted cytotoxic therapy kills persisting HIV infected cells during ART

Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

P304

4077-4090

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI82314

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P50

David C Montefiori

P577

2015-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26413868

http://www.w3.org/2001/XMLSchema#string

P921

P932

4639974

http://www.w3.org/2001/XMLSchema#string